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Sialic acid and glucuronic acid are monocarboxylated
monosaccharides, which are normally present in sugar
side chains of glycoproteins, glycolipids, and glycosami-
noglycans. After degradation of these compounds in ly-
sosomes, the free monosaccharides are released from
the lysosome by a specific membrane transport system.
This transport system is deficient in the human heredi-
tary lysosomal sialic acid storage diseases (Salla disease
and infantile sialic acid storage disease, OMIM 269920).
The lysosomal sialic acid transporter from rat liver has
now been purified to apparent homogeneity in a recon-
stitutively active form by a combination of hydroxyap-
atite, lectin, and ion exchange chromatography. A 57-
kDa protein correlated with transport activity. The
transporter recognized structurally different types of
acidic monosaccharides, like sialic acid, glucuronic
acid, and iduronic acid. Transport of glucuronic acid
was inhibited by a number of aliphatic monocarboxy-
lates (i.e. lactate, pyruvate, and valproate), substituted
monocarboxylates, and several dicarboxylates. cis-Inhi-
bition, trans-stimulation, and competitive inhibition ex-
periments with radiolabeled glucuronic acid as well as
radiolabeled L-lactate demonstrated that L-lactate is
transported by the lysosomal sialic acid transporter.
L-Lactate transport was proton gradient-dependent, sat-
urable with a Km of 0.4 mM, and mediated by a single
mechanism. These data show striking biochemical and
structural similarities of the lysosomal sialic acid trans-
porter with the known monocarboxylate transporters of
the plasma membrane (MCT1, MCT2, MCT3, and Mev).
The major function of lysosomes is the degradation of a large
variety of intra- and extracellular macromolecules. The release
of degradation products from the lysosome is accomplished by
specific membrane transport systems. More than 20 lysosomal
transporters have been characterized for specific solutes like
amino acids, sugars, nucleosides, ions, and vitamins (1). Their
fundamental role in biology is illustrated by the occurrence of
two human inherited diseases with a defective lysosomal trans-
port function, cystinosis and sialic acid storage diseases (2).
Sialic acid storage diseases are autosomal recessive disorders
that are characterized by mental retardation and a variable
degree of neurodegeneration. Lysosomal accumulation and ex-
cessive urinary excretion of free sialic acid are pathognomonic
findings. Previously, we have characterized a carrier in the
lysosomal membrane with substrate specificity for the acidic
monosaccharides sialic acid (Neu5Ac)1, uronic acids, and al-
donic acids (3). Subsequent studies in our laboratory showed
that a defective transport of sialic and glucuronic acid (GlcA) is
the primary defect in both clinical variants (4), Salla disease
and infantile sialic acid storage disease. Recently, the gene for
these disorders has been localized to the same refined chromo-
somal area on 6q14-q15 by linkage disequilibrium analysis (5).
However, the disease gene has not been identified yet. The
elucidation of the molecular structure and functional proper-
ties of the lysosomal sialic acid transporter is indispensable for
further understanding of the molecular defect(s) in the clinical
heterogeneous forms of sialic acid storage diseases. Previously,
we have developed a functional reconstitution system for the
sialic acid transporter that provided the tool to start the puri-
fication and functional characterization of the transport
protein (6).
In this paper we present the purification of the sialic acid
transporter from lysosomal membranes of rat liver to apparent
homogeneity. Its functional properties are compared with those
of other monocarboxylate transporters present in the plasma
membrane of various mammalian cells (7–9).
EXPERIMENTAL PROCEDURES
Materials
Highly purified lysosomal membrane vesicles were isolated from
livers of adult Wistar rats (3). The lysosomal membrane vesicles were
suspended at a protein concentration of 8–10 mg/ml in 20 mM NaHepes,
pH 7.4, 1 mM EDTA and were stored at 270 °C. All chemicals used were
obtained from Sigma or as indicated. L-Iduronic acid, sodium salt was
obtained from Toronto Research Chemicals Inc. (North York, ON, Can-
ada). All the tested carboxylates were titrated with NaOH before use.
Reconstitution
Reconstitution of the protein eluates into liposomes was performed
as described earlier (6), with the following modification: proteolipo-
somes were formed by incubating the protein sample, containing deter-
gent and phospholipid (total volume, 170 ml), with 150 ml of Amberlite
XAD-2 beads (Fluka) in 20 mM NaHepes, pH 7.4, 100 mM KCl. After 30
min of rotation at room temperature, beads were removed by short
centrifugation, and proteoliposomes were used for transport assays.
Transport Assay
After reconstitution, the carrier activity was assayed by uptake of
radiolabeled GlcA in the presence of an inwardly directed proton gra-
dient. Because Neu5Ac and GlcA are transported by the same lysosomal
transporter for acidic monosaccharides (3, 4), we have performed all
studies using radiolabeled GlcA, which was more readily available.
Aliquots of proteoliposomes (25 ml) were incubated at 37 °C with 5 ml of
240 mM Mes (free acid) containing 2 mCi of D-[1-3H]GlcA (Amersham
Pharmacia Biotech; specific activity, 6.6 Ci/mmol), resulting in an ex-
travesicular pH of 5.5 and a final concentration of 10 mM GlcA. Blank* This work was supported in part by the Dutch Organization for
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values were determined by incubation of proteoliposomes at 37 °C with
40 mM Mes (free acid), 7 mM unlabeled NaGlcA, pH 5.5, and 2 mCi of
D-[1-3H]GlcA and subtracted from all determinations. Previous experi-
ments showed that uptake rates are linear up to 1 min. After 1 min, the
reactions were stopped by diluting the sample with 70 ml of ice-cold
incubation buffer (17 mM NaHepes, 84 mM KCl, 40 mM Mes (free acid),
pH 5.5). The samples were immediately applied to a Sephadex G50 fine
(Amersham Pharmacia Biotech) column (Pasteur pipettes, 0.5 3 5cm)
at 4 °C. Columns were equilibrated in cold incubation buffer, and ves-
icles were eluted with 1 ml of cold incubation buffer. Vesicle-associated
radioactivity was determined by liquid scintillation counting in 10 ml of
Insta-gel (Packard).
cis-Inhibition experiments were performed by incubating the proteo-
liposomes for 1 min at 37 °C with 2 mCi of [3H]GlcA (final concentration,
10 mM) in 40 mM Mes (free acid), resulting in an inwardly directed
proton gradient (pHin 5 7.4 . pHout 5 5.5), and 7 mM of the tested
compound.
For trans-stimulation studies, a 60% proteoliposome solution (25 ml)
was pre-incubated for 60 min at 37 °C with 17 mM NaHepes, 84 mM
KCl, 40 mM Mes acid, pH 5.5, plus 10 mM monensin, 10 mM valinomycin
(Boehringer Mannheim) in the presence or absence of 1 mM unlabeled
substrate. The assay was started by adding 75 ml of an equivalent buffer
containing 2 mCi of [3H]GlcA at 37 °C with a final concentration of 0.25
mM. When the samples were pre-incubated without unlabeled sub-
strate, the external final concentration was corrected as in the case of
preloading (0.25 mM unlabeled compound). After 1 min, the reaction
was stopped as described (6).
The experiments with [14C]L-lactate (Amersham Pharmacia Biotech;
specific activity, 152 mCi/mmol) were largely performed as described for
[3H]GlcA. However, incubation mixtures contained 0.066 mCi of [14C]L-
lactate (final concentration, 15 mM) and were performed at 20 °C instead
of 37 °C. Blank values were determined by incubation of proteolipo-
somes with 40 mM Mes (free acid), 7 mM unlabeled sodium L-lactate and
subtracted from all determinations. For protein side chain modification,
proteoliposomes (100 ml) were incubated and treated as described (6).
Purification of the Rat Liver Lysosomal Membrane
Sialic Acid Transport Protein
For a single purification, lysosomal membrane vesicles prepared
from 150 g of rat livers (15 rats) were used.
Step 1: Solubilization—Solubilization of lysosomal membrane pro-
teins was performed by mixing the lysosomal membrane vesicles 1:1
(v/v) with 1% Triton X-100 (especially purified for membrane research,
Boehringer Mannheim), 20 mM Tris-HCl, pH 7.4. After 25 min of incu-
bation at 0 °C, unextracted material was pelleted by ultracentrifugation
at 150,000 3 g in a Beckman SW 40 rotor for 20 min at 4 °C.
Step 2: Hydroxyapatite—The Triton X-100 extract was applied to
hydroxyapatite columns (Pasteur pipettes containing 0.5 g of dry ma-
terial, Biogel HTP, Bio-Rad, packed by 15 s of tapping) at 4 °C, with a
maximum of 500 ml solubilized material/column. Each column was
washed with 3 ml of 20 mM Tris-HCl, pH 7.4, 0.1% Triton X-100 (buffer
A). Elution was with 3 ml of buffer A, 25 mM Na2HPO4, NaH2PO4, pH
7.4. After pooling all the 3-ml eluates, a 2-ml sample was concentrated
in a Centricon 10 device (Amicon, Inc., Beverly, MA) until 100–150 ml
and desalted. A 50-ml aliquot was used for the reconstitution assay and
a 20-ml aliquot was used for the protein assay. Desalting was performed
on a 2-ml Sephadex G50 medium (Amersham Pharmacia Biotech) col-
umn equilibrated in buffer A (10).
Step 3: Lentil Lectin—The eluates of the different hydroxyapatite
columns were pooled and applied to a 2-ml lentil lectin affinity chro-
matography column (lentil lectin-Sepharose 4B, Amersham Pharmacia
Biotech) pre-equilibrated in buffer A. After washing the lentil lectin
column with 2 ml of buffer A, the flow-through fraction (unretained
material) was applied to a 2-ml DEAE-Sephacel (Amersham Pharmacia
Biotech) anion exchanger pre-equilibrated in buffer A containing 10%
glycerol (buffer B). A 2-ml sample of the lentil lectin flow-through
fraction was concentrated in a Centricon 10 device to 100–150 ml and
desalted (10). A 50-ml aliquot was used for the reconstitution assay, and
a 20-ml aliquot was used for the protein assay.
Step 4: DEAE-Sephacel—After extensive washing the DEAE-Sepha-
cel column with 20 ml of buffer B and 20 ml of buffer B with 40 mM
NaCl, bound material was eluted with 6 ml of buffer B with 100 mM
NaCl. This fraction was stored at 270 °C.
Step 5: Hydroxyapatite—After the DEAE-eluate was thawed, a 0.5
ml sample was concentrated in a Centricon 10 device until 100 ml and
desalted (10). A 50 ml aliquot was used for the reconstitution assay and
a 20 ml aliquot for the protein assay. The 100 mM NaCl DEAE-eluate
(5.5 ml) was adjusted to pH 6.0 with 0.5 M Mes (free acid) and applied
to a prepacked hydroxyapatite column (1-ml EconoPac HTP cartridge,
Bio-Rad) pre-equilibrated in 300 mM NaCl, 20 mM NaMes pH 6.0, 0.1%
Triton X-100. Transport activity was eluted with 6 ml of 1 mM
Na2HPO4, NaH2PO4, pH 6.0, 300 mM NaCl, 0.1% Triton X-100. This
eluate was concentrated in Millipore ultrafree-15 centrifugal filters 10K
(Millipore Corporation, Bedford) to approximately 300 ml and desalted
(10). A 50-ml aliquot was used for the reconstitution assay, and a 100-ml
aliquot was used for the protein assay.
Step 6: Mono Q—The concentrated hydroxyapatite eluate (150 ml)
was applied to a 0.10-ml Mono Q anion exchange column attached to a
Amersham Pharmacia Biotech SMART system. This column was equil-
ibrated in buffer B, and bound material was eluted with a linear
gradient of 0–210 mM NaCl in buffer B. Fractions of 0.1 ml were
collected and pooled pairwise, buffer was exchanged for 20 mM Na-
Hepes, 100 mM KCl, 0.1% Triton X-100 by the desalting procedure as
described above, and a 50-ml aliquot was used for the reconstitution
assay. All column procedures were performed at 4 °C.
Protein Characterization and Determination
The purity of the various active fractions was determined by SDS-
polyacrylamide gel electrophoresis according to Laemmli (11) of meth-
anol/chloroform precipitated samples (12), followed by Coomassie Bril-
liant Blue R-250 or the silver nitrate staining according to Amersham
Pharmacia Biotech. Protein concentration was determined by the pro-
cedure of Lowry et al. as modified by Peterson (13) for the presence of
Triton. Protein concentrations in eluates of the second hydroxyapatite
column were determined after methanol/chloroform precipitation (12).
Protein concentrations in Mono Q eluates were too low to be determined
by the above assay and were therefore estimated from silver-stained
SDS-PAGE gels.
For the endoglycosidase F/N-Glycosidase F (Boehringer Mannheim)
treatment of the purified protein, the Mono Q fractions 19–23 were
pooled, concentrated, and incubated with 25 milliunits endoglycosidase
F, 100 ml in the presence of 20 mM potassium phosphate buffer, pH 7.4,
50 mM EDTA, 2% Triton X-100, 0.2% SDS, 2% b-mercaptoethanol for
2 h at 37 °C. Proteins were precipitated with methanol/chloroform (12).
The pellet was resuspended in sample buffer and analyzed by SDS-
PAGE (10% gel).
RESULTS
Purification of the Lysosomal Sialic Acid Transporter—Var-
ious membrane (transport) proteins have been successfully pu-
rified using hydroxyapatite as well as ion exchange chromatog-
raphy in the presence of detergents (14–18). In addition,
affinity chromatography with oligosaccharide-specific lectins
has been used to identify the major heavily glycosylated lyso-
somal membrane proteins: LAMPs (lysosomal-associated mem-
brane proteins) and LIMPs (lysosomal integral membrane pro-
teins) (19–22). Based on the success of these purification
methods for membrane proteins we developed a purification
protocol for the lysosomal sialic acid transporter. Previously,
we have reported a successful reconstitution procedure for the
rat liver lysosomal sialic acid transporter that now provided
the functional assay to follow fractionation and purification of
the solubilized transporter (6). At all steps of the purification
procedure, samples were collected and reconstituted into pro-
teoliposomes, and their transport activities were measured us-
ing radiolabeled GlcA as a substrate (Table I).
The Triton X-100 solubilized lysosomal membrane proteins
were applied to small columns of dry hydroxyapatite material.
The columns were washed with equilibration buffer at pH 7.4,
and about 20% of the transport activity was eluted with 25 mM
sodium phosphate buffer at pH 7.4. This resulted in a 4-fold
purification. The next step consisted of lentil lectin affinity
chromatography. Almost all activity of the sialic acid trans-
porter was recovered from the column flow-through. Lentil
lectin recognizes a-D-glucose and a-D-mannose residues and
therefore binds glycoproteins. Consequently, a number of ma-
jor lysosomal membrane glycoproteins bound to the column
and thus could be separated from the protein preparation con-
taining transport activity. This step was kept in our protocol
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despite the fact that it did not lead to an increase in specific
activity.
The lentil lectin flow-through fraction was applied to a
DEAE-Sephacel anion exchange column. With 100 mM NaCl,
12% of the total transport activity was eluted. As depicted in
Table I, this resulted in a '14.5-fold increase in specific activ-
ity over the starting material. Analysis of the protein composi-
tion of fractions obtained from these initial purification steps is
shown in Fig. 1. Many different protein bands were still
present.
The next purification step consisted of chromatography on
hydroxyapatite. This time the column was pre-equilibrated at
pH 6.0 in the presence of 300 mM NaCl. Under these conditions,
acidic proteins are retained and are eluted with low phosphate
buffers. This step provided an important purification of the
sialic acid transport protein with an 80-fold enrichment in
specific activity (Table I). SDS-PAGE protein analysis using
silver staining showed at least four distinct protein bands (Fig.
2A). One of these proteins has a molecular mass of 85 kDa and
based on its N-terminal amino acid sequence represented one
of the major lysosomal membrane glycoproteins, the Lgp85 or
LIMP II (23). Another major 67-kDa protein represented the
lysosomal membrane-bound subunit of acid phosphatase (24).
The other proteins were considered as candidates for the lyso-
somal sialic acid transporter.
The next purification step consisted of a strong anion ex-
change Mono Q column attached to the SMART system of
Amersham Pharmacia Biotech. Retained proteins were eluted
with a gradient of 0–210 mM NaCl. SDS-PAGE analysis by
silver nitrate staining of the eluted proteins showed a predom-
inant protein band with a molecular mass of '57 kDa in the
fractions 20/21 in which also the highest GlcA transport activ-
ity was observed (Fig. 2B). In addition, quantitative image
analysis of the SDS-PAGE protein elution pattern from the
Mono Q column demonstrated a correlation between the 57-
kDa protein and the transport activity (data not shown). All
other visualized proteins could not represent the sialic acid
transporter, because they became more prevalent in following
fractions, where lower or no transport activity was detected
(Fig. 2B).
In the final protein preparations (fractions 20–21 from the
Mono Q column) transport activity was 432-fold enriched over
the activity in the initial lysosomal membrane extract (Table I).
Considering that the lysosomal membrane marker b-glucosi-
dase is about 100-fold enriched in the lysosomal membrane
vesicles (used as a starting material), the sialic acid transport
protein is about 40,000-fold purified in the final eluate of the
Mono Q column.
Properties of the Purified Lysosomal Sialic Acid Transport-
er—To investigate the glycosylation of the transporter, the
final protein preparation was incubated with the enzyme mix-
ture endoglycosidase F/N-glycosidase F. After treatment, the
apparent molecular mass of the 57-kDa protein was not de-
creased. The apparent molecular mass of a control glycoprotein
was decreased as a result of cleavage of glycosydic chains (data
not shown). This, together with the observation that this pro-
tein did not interact with lentil lectin, indicates that the carrier
is apparently not glycosylated. Analysis by SDS-PAGE in the
presence or absence of the thiol-reducing agent 2-mercaptoeth-
anol did not show any alteration of the electrophoretic behavior
of the purified transport protein (data not shown). This indi-
cates that the transporter is not functional as a (homo)dimer or
polymer linked by disulfide bridges.
Substrate Specificity of the Lysosomal Sialic Acid Transport-
er—Because the final yield of the highly purified sialic acid
transporter was very low, detailed kinetic studies were difficult
to perform. Therefore, most kinetic characterization of the ly-
sosomal sialic acid transporter was performed using partially
purified preparations (DEAE-Sephacel eluates). Subsequently,
some key experiments were repeated in a concise manner with
the highly purified transport preparation.
Interaction of the Lysosomal Sialic Acid Transporter with
Iduronic Acid—In earlier substrate specificity studies with the
crude lysosomal sialic acid transporter, we have shown that
this transporter recognizes structurally different types of acidic
monosaccharides (i.e. the sialic acid Neu5Ac and the uronic
acid GlcA) (3, 4). The uronic acid iduronate (IdoA) represents,
FIG. 1. SDS-PAGE of protein fractions during the initial steps
of the purification of the functional lysosomal sialic acid trans-
porter from rat liver. Protein fractions were analyzed by SDS-PAGE
(10% gel) and Coomassie Brilliant Blue R-250 stained. Per lane, an
aliquot of approximately 30 mg of total protein was loaded. Lane 1,
mid-range protein molecular weight markers (Promega). Lane 2, rat
liver lysosomal membrane vesicles. Lane 3, Triton X-100-solubilized
lysosomal membrane vesicles. Lane 4, 25 mM sodium phosphate eluate
of first hydroxyapatite column. Lane 5, lentil lectin unretained fraction.
Lane 6, 100 mM NaCl eluate of DEAE-Sephacel column.
TABLE I
Purification of the sialic acid transporter from rat liver lysosomal membrane vesicles
Lysosomal membrane vesicles (approximately 25 mg of protein) derived from 150 g of rat livers were used as starting material. The purification
procedure, reconstitution, and transport assay were performed as described under “Experimental Procedures.” Activity is expressed as uptake of
[3H]GlcA in 1 min at 37 °C. Data represent the means of three separate isolations.
Fraction Protein Total protein Total Activity Yield Specific activity Foldenhancement
mg/ml mg pmol/min % pmol GlcA/mg/min
Solubilized lysosomal
membrane extract
200 12000 2102.4 100 175.2 1
First hydroxyapatite eluate 16.4 591 441.5 21 747.3 4
Lentil lectin eluate 13.6 489 378.4 18 774.4 4.4
DEAE eluate 16.6 99.5 252.3 12 2534.9 14.5
Second hydroxyapatite
eluate
0.5 3.0 42.1 2 14171.4 80
Mono Q eluate 0.14 0.028 2.1 0.1 75757.6 432
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like GlcA, a major component of glycosaminoglycans. These are
degraded in lysosomes, and thus free IdoA is like GlcA expected
to be transported across the lysosomal membrane. The recent
commercial availability of free IdoA made it now possible to
investigate by cis-inhibition and trans-stimulation studies
whether this uronic acid is also a substrate for the lysosomal
sialic acid transporter (Table II). IdoA inhibited [3H]GlcA up-
take, although less efficiently than Neu5Ac and GlcA. Further-
more, IdoA was able to induce, like its isomer GlcA, almost a
2-fold trans-stimulation (Table II). These experiments indicate
that IdoA is indeed a substrate for the sialic acid transporter.
Interaction of the Lysosomal Sialic Acid Transporter with
Small Monocarboxylates—We investigated the interaction of
the transport protein with other known substrates for organic
anion carriers. Initially, mono-, di-, and tricarboxylic acids
were tested for their cis-inhibition effect on the initial linear
rate of proton-driven [3H]GlcA uptake in a partially purified
preparation (Table II). Most of these organic anions are known
substrates for the proton-driven monocarboxylate transporters
MCT1, MCT2, and MCT3 of the plasma membrane and for the
pyruvate and the dicarboxylate transporters of the outer mito-
chondrial membrane. The monocarboxylic and dicarboxylic ac-
ids were all strong inhibitors, except for the amino acid gluta-
mate and the Krebs cycle intermediate a-ketoglutarate.
L-Lactate and the anti-epileptic drug valproic acid (dipropyl
acetate), among the monocarboxylates, and succinate, among
the dicarboxylates, were the strongest inhibitors (Table II). The
tricarboxylate citrate showed no significant inhibition. To test
whether inhibition represents interaction at the substrate
binding site and consequently transport, we investigated the
trans-stimulation effect of some representative mono- and di-
carboxylate inhibitors on the uptake of [3H]GlcA. Partially
purified protein preparations were reconstituted in proteolipo-
somes and preloaded with an unlabeled compound at concen-
trations of 1 mM, just above the Km of GlcA (0.4 mM) (6), and the
uptake of [3H]GlcA was followed for 1 min. As shown in Table
II, L-lactate as well as GlcA itself trans-stimulated the uptake
of [3H]GlcA. Mevalonate and succinate did not cause trans-
stimulation. Next, we investigated transport kinetics of L-lac-
tate by the partially purified sialic acid transporter using ra-
diolabeled [14C]L-lactate. The presence of an inwardly directed
proton gradient (pHin 5 7.4 . pHout 5 5.5) stimulated initial
uptake rates of lactate above equilibrium level (Fig. 3). At the
top of overshoot, approximately 2% of external lactate was
taken up inside the vesicles. This overshoot phenomenon was
abolished in the absence of a proton gradient (pHin 5 pHout 5
7.4), indicating that the transport of lactate is proton gradient-
driven, similarly to the transport of the acidic monosaccharides
Neu5Ac and GlcA. In these experiments, the use of low concen-
FIG. 3. Proton gradient-dependent uptake of [14C]L-lactate.
Proteoliposomes of DEAE-Sephacel eluate prepared in 20 mM NaHepes,
100 mM KCl, pH 7.4, were incubated with 15 mM [14C]L-lactate at 20 °C
in 40 mM Mes (free acid), 10 mM valinomycin, pH 5.5 (with proton
gradient, pHin 5 7.4 . pHout 5 5.5, l) or in 20 mM NaHepes, 10 mM
valinomycin, pH 7.4 (no proton gradient, pHin 5 pHout 5 7.4, E).
FIG. 2. A 57-kDa protein correlates with the transport activity.
Panel A shows the SDS-PAGE protein pattern of the preparation, which
was applied to the Mono Q column. Panel B, bottom, elution profile of
Mono Q column. Transport activity was measured in reconstituted
proteoliposomes of the respective Mono Q fractions. Proteoliposomes
(25 ml) were incubated 1 min at 37 °C with 10 mM [3H]GlcA in the
presence of an inwardly directed proton gradient. Transport activity is
expressed as pmol [3H]GlcA/min/25 ml. Top, SDS-PAGE and silver
staining of corresponding Mono Q fractions.
TABLE II
cis-Inhibition and trans-stimulation of [3H]GlcA uptake by mono-,
di-, or tricarboxylic acids
The partially purified (DEAE-Sephacel eluate) sialic acid transporter
was reconstituted, and proteoliposomes were incubated 1 min at 37 °C
with 10 mM [3H]GlcA in the presence of an inwardly directed proton
gradient and 7 mM of the indicated compounds. Data represent the
means of four independent determinations 6 S.D. In trans-stimulation
experiments partially purified proteoliposomes were preincubated for
60 min at 37 °C in the presence or absence of 1 mM unlabeled GlcA,
IdoA, L-lactate, mevalonate, or succinate in 20 mM NaHepes, 100 mM
KCl, 40 mM Mes, pH 5.5, 10 mM valinomycin and monensin. The trans-
port assay was started by a 4-fold dilution in pH 5.5 incubation buffer
with 2 mCi of [3H]GlcA and allowed to proceed for 1 min. In the samples
that were preincubated without unlabeled compound, 0.25 mM unla-
beled compound was added together with radiolabeled substrate to give
the same extravesicular substrate concentration in both experiments.
Transport activity trans-Stimulation
pmol/mg/min % of control % of not trans-
stimulated
Control 2280.5 6 132.6
Acidic monosaccharides
GlcA 0 0 200
Neu5Ac 0 0
IdoA 916.1 6 272.4 40 180
Monocarboxylates
Oxamate 553.0 6 45.5 24
Pyruvate 534.6 6 46.0 24
L-Lactate 195.6 6 67.8 8 150
4-OH-butyrate 369.4 6 107.2 16
Mevalonate 510.0 6 24.0 22 109
Valproate 0 0
Dicarboxylates
Succinate 0 0 79
Malate 366.0 6 21.8 16
Malonate 685.3 6 37.5 30
Maleate 592.5 6 79.5 26
Fumarate 234.3 6 81.0 10
a-Ketoglutarate 1090.2 6 199.6 48
Glutamate 2437.8 6 195.4 107
Tricarboxylate
Citrate 1665.9 6 30.6 73
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trations of lactate (15 mM), lower temperature (20 °C), and the
use of a pH far above the pK for the tested compounds limit the
contribution of aspecific diffusion on the net uptake. Proton-
driven [14C]L-lactate transport under apparent zero-trans con-
ditions was saturable with a Km of approximately 0.4 mM and
a Vmax of 500 nmol/30 s/mg protein. An Eadie-Hofstee plot of
the kinetic data indicated a linear process, suggesting that only
one type of transport system operates (data not shown).
Although these studies provide evidence that the partially
purified protein preparation is able to transport, in addition to
acidic monosaccharides, many other small monocarboxylic ac-
ids, it cannot be excluded that other proteins in this prepara-
tion are present. However, the exchange of GlcA with L-lactate
in the trans-stimulation experiments is strong evidence for
transport of both compounds by the same protein. To provide
further evidence that lactate and GlcA can be transported by
the same carrier in the lysosomal membrane, competitive in-
hibition experiments were performed. Proton-dependent trans-
port of [3H]GlcA or [14C]L-lactate was measured in voltage
clamped membranes with K1/valinomycin in the absence or
presence of cold L-lactate or cold Neu5Ac as inhibitors, respec-
tively. The results were fitted to a double reciprocal plot, show-
ing a clear mode of competitive inhibition of lactate (calculated
Ki of 2.5 mM) on GlcA transport and of Neu5Ac (calculated Ki of
2 mM) on L-lactate transport (Fig. 4). Definite evidence that
transport of lactate is performed by the lysosomal sialic acid
transporter was obtained from cis-inhibition and concentration-
dependent inhibition studies with the highly purified sialic acid
transporter preparation. Proton-driven [3H]GlcA transport un-
der apparent zero-trans conditions was completely inhibited in
the presence of 7 mM unlabeled GlcA or Neu5Ac or L-lactate
(Table III). Proton-driven [14C]L-lactate transport under appar-
ent zero-trans conditions was inhibited totally by L-lactate and
significantly by Neu5Ac. It is interesting to note that under
these conditions GlcA did not inhibit. Because the GlcA trans-
port assays are performed at 37 °C and the lactate transport
assays at 20 °C, these apparent inconsistencies can be ex-
plained by differences in affinities at different temperatures.
Inhibition of [3H]GlcA transport by L-lactate was a clear con-
centration-dependent process (Table III). Clearly, the highly
purified transporter preparation contains a transporter that
carries all three substrates, GlcA, Neu5Ac, and L-lactate (see
also the above competitive inhibition experiments).
Sensitivity to Covalent Protein Modifiers—In previous exper-
iments studying the effect of protein modifiers on GlcA trans-
port in native lysosomal membrane vesicles and reconstituted
proteoliposomes, we have demonstrated the involvement of
arginines (and possibly histidines) in substrate recognition (3,
6). To investigate whether L-lactate transport is similarly af-
fected by some of these protein modifiers, inhibition and sub-
strate protection experiments were performed. 1 mM N-ethyl-
maleimide, a thiol-modifier, irreversibly inactivated transport
of both GlcA (75% inhibition) and L-lactate (86% inhibition) in
proteoliposomes from partially purified preparations. Phenyl-
glyoxal, under these conditions an arginine modifier, signifi-
cantly inhibited GlcA transport (44% of uninhibited rate). The
inactivation of GlcA transport could be partially rescued when
phenylglyoxal treatment was performed in the presence of the
substrates GlcA, Neu5Ac, and L-lactate (96, 96 and 56% of
uninhibited rate, respectively). Similarly, L-lactate transport
was significantly inhibited by phenylglyoxal (59% of uninhib-
ited rate) and protected in the presence of L-lactate, GlcA, and
Neu5Ac (91, 88, and 71%, respectively, of uninhibited rate).
Apparently, GlcA, Neu5Ac, and L-lactate all use the same sub-
strate-binding site of the transport protein.
DISCUSSION
In this paper we describe the purification of the lysosomal
sialic acid transport protein to apparent homogeneity based on
its biological activity. To our knowledge, this is the first report
TABLE III
cis-Inhibition of [3H]GlcA and [14C]L-lactate uptake by GlcA, Neu5Ac,
and L-lactate in proteoliposomes of the highly purified lysosomal sialic
acid transporter
In the upper part of the table, the Mono Q eluate was reconstituted,
and proteoliposomes were either incubated 1 min at 37 °C in the case of
[3H]GlcA assay or 30 s at 20 °C in the case of [rosup;14C]L-lactate assay,
both in the presence of an inwardly directed proton gradient and with
7 mM of the indicated compounds. In the lower part of the table,
proteoliposomes of the highly purified sialic acid transporter were in-
cubated with 10 mM [3H]GlcA for 1 min at 37 °C in the presence of an
inward directed proton gradient (pHin 5 7.4, pHout 5 5.5) and with





pmol/min/assay % of control pmol/30 s/assay % of control
Control 0.082 15.4
GlcA 0 0 16.2 105
Neu5Ac 0 0 8.8 57
L-Lactate 0 0 0 0
L-Lactate
10 mM 0.082 100
20 mM 0.075 92
50 mM 0.066 81
150 mM 0.059 72
500 mM 0.010 12
FIG. 4. Competitive inhibition of
[3H]GlcA transport by L-lactate and
of [14C]L-lactate transport by Neu5Ac.
Initial proton-dependent transport rates
of [3H]GlcA (1 min, 37 °C) and [14C]L-lac-
tate (30 s, 20 °C) were measured in pro-
teoliposomes of DEAE-Sephacel eluates.
The uptake medium contained increasing
concentrations of the respective sub-
strates in the presence or absence of the
inhibitors L-lactate or Neu5Ac. Data were
plotted double reciprocally. A, [3H]GlcA
uptake with (E) or without (l) cold 2 mM
L-lactate. B, [14C]L-lactate uptake with
(E) or without (l) cold 7 mM Neu5Ac.
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about the purification and detailed kinetic characterization of a
lysosomal membrane carrier protein. Initial attempts using
specific inhibitors like a-cyanocinnamate as ligands for affinity
chromatography have not been successful.2 Classical chromato-
graphic techniques for membrane proteins were used. Hy-
droxyapatite chromatography was particularly successful in
obtaining fractions enriched in transport activity. This medium
has also been successful in the purification of several mitochon-
drial membrane transport proteins (14). Like some of those
carriers, our transporter adsorbed weakly to hydroxyapatite
(elution with 25 mM and 1 mM sodium phosphate buffer). This
is probably due to a large micellar shell around the protein
formed by Triton X-100 molecules. Silver-stained SDS-PAGE
gels showed only one protein band with a molecular mass of
approximately 57 kDa, correlating with the transport activity
of GlcA (Fig. 2B). Concerning the enrichment of this lysosomal
membrane transporter and the highly sensitive silver staining,
it is unlikely that the activity resides in another minor, not
visualized protein. Apparently, the more abundant and well
characterized integral lysosomal membrane proteins, such as
LAMPs and LIMPs, are densely N-glycosylated glycoproteins
(22). Based on the deglycosylation studies, the sialic acid trans-
porter appears not to be heavily glycosylated. For several
known anion carriers N-glycosylation is not required for their
transport function (25). The same is true for some other mem-
brane transporters (26, 27). Some sugar carriers are known to
be functional because homodimers possibly linked by S–S
bridges (28, 29). In contrast, our transporter does not have a
quaternary structure in which subunits are held together by
S–S bridges.
In previous studies, we showed that the structural require-
ments for recognition of the substrate by the carrier were
different from those of other proteins involved in sialic acid
metabolism (lysosomal sialidase, the Golgi system transporter
for CMP-sialic acid and sialyltransferases). For the carrier, the
C-1 carboxylic group had to be unsubstituted as well as the
native hydroxyl group at C-2 (3). In addition, the kinetic prop-
erties of the lysosomal sialic acid transporter were similar to
those of other known proton cotransporters for other organic
anions (3, 6). Structurally different monosaccharides, such as
sialic acid (N-acetylneuraminic acid) (a 9-carbon N-substituted
monosaccharide), glucuronic acid (a hemiacetal-forming acid
monosaccharide with a C-6 carboxylic group), and gluconic acid
(a non-hemiacetal-forming acid monosaccharide with a C-1 car-
boxylic group) are all recognized by this carrier (3, 6). In this
paper we extended the group of acidic monosaccharide sub-
strates with IdoA, like GlcA an important physiological com-
ponent of mammalian glycosaminoglycans. The lysosomal
sialic acid transporter is the only mammalian transporter
known to allow transport of uronic acids, aldonic acids, and
N-substituted neuraminic acids (3, 4). The physiological role of
sialic acid and glucuronic acid transport has earlier been dem-
onstrated by the accumulation of these monosaccharides and
by their defective transport in lysosomes of patients with sialic
acid storage diseases (4, 30). So far, lysosomal accumulation of
IdoA in these patients has not been investigated. The contri-
bution of the different acidic monosaccharides to the pathology
remains therefore elusive.
Because aliphatic monocarboxylates like pyruvate inhibit
transport (3), we compared the biochemical characteristics of
the purified carrier with those of the aliphatic monocarboxylate
transporters. To date, several monocarboxylate transporters
present in the plasma membrane of various mammalian cells
have been cloned and characterized: MCT1, MCT2, and MCT3
(7–9, 31). They are proton-coupled transporters with a broad
specificity for short chain monocarboxylates (including lactate
and pyruvate), showing differences in cellular distribution. A
number of non-sugar mono- and dicarboxylic acids were effec-
tive inhibitors of initial uptake rates of GlcA transport by the
partially purified lysosomal sialic acid transporter (Table II).
The inhibition observed was not dependent on changes in mem-
brane potential, because experiments were performed in the
presence of K1 and valinomycin. These monocarboxylates are
transported by the MCTs with different affinities, except me-
valonate (7). Mevalonate is transported by Mev, a homologue of
MCT1 from Chinese hamster ovary cells (32), but is not trans-
ported efficiently by MCT1 (8). trans-Stimulation experiments
demonstrated that mevalonate is not transported by the lyso-
somal sialic acid transporter (Table II). Most of the tested
dicarboxylates are known to be substrates of the dicarboxylate
carrier in mitochondria (e.g. succinate, malate, and malonate)
(33). For the di- and tricarboxylic acids glutamate, a-ketoglut-
arate, and citrate specific mitochondrial transport proteins
have been identified (34). The lack of trans-stimulation in our
experiments suggested that one of the strongest dicarboxylate
inhibitors (i.e. succinate) is not transported by the lysosomal
sialic acid transporter. Similarly, a lactate transporter in pla-
cental brush border membrane vesicles is unable to transport
the cis-inhibitor succinate (35).
Transport of [3H]GlcA by the partially purified lysosomal
sialic acid transporter is cis-inhibited and trans-stimulated by
the small aliphatic monocarboxylate L-lactate. This inhibition
of [3H]GlcA transport by L-lactate showed a competitive mode.
The same cis-inhibition of [3H]GlcA transport by L-lactate was
observed using the highly purified preparation, containing one
major protein band on SDS-PAGE. This inhibition was clearly
dependent on the concentration of the inhibitor L-lactate.
Transport of [14C]L-lactate by the partially purified lysosomal
sialic acid transporter preparation is a proton gradient-medi-
ated process that can be competitively inhibited by Neu5Ac but
surprisingly not by GlcA. [14C]L-lactate transport by the highly
purified preparation also showed clear inhibition by Neu5Ac
but not by GlcA. Apparently, at 37 °C ([3H]GlcA transport
assay) as well as GlcA, Neu5Ac, and L-lactate are recognized by
the transporter, but at 20 °C ([14C]L-lactate transport assay)
the affinity for L-lactate and Neu5Ac is much higher than for
GlcA. This can be explained by structural differences among
these molecules, especially at the site of the carboxyl group.
Another possible explanation would be the presence of different
lactate transporters, one of which is not fully inhibited by the
other two compounds. However, kinetic analysis (linear Eadie-
Hofstee plots) did not show any evidence for different lactate
transporters. In conclusion, all these data provide strong evi-
dence that the lysosomal sialic acid transporter is able to trans-
port besides acidic monosaccharides also other short chain
monocarboxylates like L-lactate. The competitive inhibition ex-
periments, the trans-stimulation experiments, and the cis-in-
hibition experiments using the highly purified preparation ex-
clude the possibility that the observed L-lactate transport is
due to a contaminating protein.
We do not know whether L-lactate is a physiological sub-
strate in the lysosome. However, a probenecid-inhibitable or-
ganic anion transporter, possibly also recognizing lactate, was
postulated in endosomes from macrophages (36). Probenecid is
also an inhibitor of the sialic acid transporter in native lysoso-
mal membranes.3 Proton cotransport of L-lactate has been de-
scribed for MCT1, MCT2, and MCT3 by kinetic analysis and by
inhibition with para-chloromercuribenzoic acid (8, 9, 31). Lac-
2 G. M. S. Mancini, unpublished results. 3 G. M. S. Mancini and F. W. Verheijen, personal observation.
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tate and pyruvate show a structural similarity with Neu5Ac, of
which pyruvate is the natural precursor. Although it would be
interesting to investigate whether MCT1 and/or MCT2 also
could transport monocarboxylic monosaccharides, it is as-
sumed that MCT1 transports mainly unbranched aliphatic
monocarboxylates from C-2 to C-5 but not mevalonate.
[3H]GlcA uptake is cis-inhibited by the anti-epileptic drug val-
proic acid. Valproic acid is also a known inhibitor of the mito-
chondrial pyruvate carrier (37) and of MCT1 in Chinese ham-
ster ovary cells (38), suggesting a similarity between the
lysosomal system here investigated and these monocarboxylate
carriers. It would be interesting to study in more detail the role
of the lysosomal sialic acid transporter in the transport of
valproic acid, its metabolites, and other organic anions by fu-
ture experiments using their radioactive forms.
Both the lysosomal sialic acid transporter and MCTs are
sensitive to hydroxycinnamic acid derivatives, the stilbene dis-
ulfonate DIDS, and para-chloromercuribenzoic acid (6–9).
However, the difference in sensitivity to the amino acid modi-
fier N-ethylmaleimide distinguishes MCT1 from the lysosomal
sialic acid transporter. MCT1 is only poorly inhibited by N-
ethylmaleimide (7) in contrast to the sialic acid transporter,
which is strongly inhibited by N-ethylmaleimide (this paper).
Another difference between the sialic acid transporter and
MCT1 is the lower Km for lactate transport, 0.4 mM (this paper)
versus 8 mM for MCT1 (9). Recently, Price et al. have cloned and
sequenced four new human MCT homologues, MCT4 to MCT7
(39). Their similarities and some strongly conserved sequence
motifs provide evidence for an ancient family of transporters.
Considering that the conversion of Phe360 into Cys changes
MCT1 from a lactate transporter to a mevalonate transporter
(8, 32), it is possible that minimal structural differences among
MCTs account for major differences in substrate specificity.
The amino acid modifier phenylglyoxal inactivated the recon-
stituted sialic acid transporter. This reagent revealed essential
arginine/histidine residues at the substrate-binding site of the
transporter, because its inactivation could be prevented by
concomitant incubation with Neu5Ac or GlcA (6). L-Lactate acts
on the same substrate-binding site as GlcA, because the inhib-
itory effect of phenylglyoxal on the uptake of [14C]L-lactate
could be prevented by concomitant incubation with L-lactate or
GlcA (this paper). Apparently, phenylglyoxal modifies essential
arginine residues present in the lactate-binding site of the
carrier protein. Also, for the MCTs an essential function for a
conserved Arg residue has been proposed (39). In conclusion,
we have observed an overlap in substrate specificity for mono-
carboxylates, a similar proton cotransport mechanism (with
consequently the sensitivity to para-chloromercuribenzoic
acid), a similar sensitivity to hydroxycinnamic acid derivatives
and stilbene disulfonates, and the presence of essential argi-
nine residues in the substrate binding sites of the sialic acid
carrier and the monocarboxylate carriers. Altogether, these
data suggest functional and structural similarities of our trans-
porter with previously characterized monocarboxylate
transporters.
The lysosomal transport mechanism for sialic acid is defec-
tive in different clinical variants of the neurodegenerative dis-
order sialic acid storage disease. We demonstrated that the
purified sialic acid transporter interacts with lactate, an im-
portant energy source in brain. Further studies of lactate me-
tabolism in brain from these patients might help to understand
events of neurodegeneration in this disorder. By NMR spec-
troscopy, it is possible to show abnormalities in metabolites in
brain (40). We are not aware of NMR spectroscopy studies in
sialic acid storage diseases, which could be applied to study
lactate metabolism in brain of these patients.
By N-terminal sequencing, we have obtained a stretch of
amino acids from the 57-kDa protein, but still too many doubt-
ful residues are present, making gene cloning difficult. How-
ever, the functional and possible structural homology with
monocarboxylate transporters may provide a tool to identify
and clone the sialic acid transporter gene by screening for
homologues in available sequence libraries.
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